J Drugs Dermatol. 2024 May 1;23(5):378-379. doi: 10.36849/JDD.7782.
Alopecia areata (AA) is a common autoimmune disorder. Although its pathogenesis is not fully understood, AA involves CD8 T cell-mediated destruction of the hair follicle. Several treatment options exist; however, there is minimal evidence in the pediatric population. Currently, there are no curative treatments for AA. The literature suggests that Janus kinase (JAK) inhibitors may be an effective treat-ment for AA, but evidence in pediatric patients is limited. Here, we report a case of severe pediatric AA treated with topical ruxolitinib, a JAK inhibitor. J Drugs Dermatol. 2024;23(5):378-379. doi:10.36849/JDD.7782.
斑秃（AA）是一种常见的自身免疫性疾病。虽然其发病机制尚未完全阐明，但 AA 涉及 CD8 T 细胞介导的毛囊破坏。目前存在多种治疗选择；然而，在儿科人群中证据很少。目前，AA 没有治愈方法。文献表明，Janus 激酶（JAK）抑制剂可能是治疗 AA 的有效方法，但儿科患者的证据有限。在这里，我们报告了一例严重的儿科 AA 患者，使用 JAK 抑制剂局部鲁索替尼治疗。J 皮肤病药物杂志。2024；23（5）：378-379. doi:10.36849/JDD.7782.
